

CONCEPT NOTE

HIV DRUG RESISTANCE

SURVEILLANCE OF HIV DRUG RESISTANCE IN ADULTS RECEIVING ART (ACQUIRED HIV DRUG RESISTANCE)

JULY 2014



SURVEILLANCE OF HIV DRUG RESISTANCE IN ADULTS RECEIVING ART (ACQUIRED HIV DRUG RESISTANCE)

JULY 2014

WHO Library Cataloguing-in-Publication Data

Surveillance of HIV drug resistance in adults receiving ART (acquired HIV drug resistance).

1. Anti-HIV agents – therapeutic use. 2. Drug resistance, Viral – drug effects. 3. HIV infections – epidemiology. 4. HIV infections – drug therapy 5. Population surveillance. I. World Health Organization.

ISBN 978 92 4 150707 3

(NLM classification: QV 268.5)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Layout by L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland.

TABLE OF CONTENTS

Acknowledgments	3
Acronyms	4
Background	5
1. Introduction	6
2. Objectives	6
3. Overview of survey approach	7
3.1 Survey methodology	7
3.2 Survey populations	7
4. Survey outcomes	8
4.1 Outcome 1a: Prevalence of viral load suppression (VL<1000 copies/mL) among individuals on ART	8
4.2 Outcome 1b: Prevalence of viral load suppression (VL<1000 copies/mL) among individuals on first-line ART	8
4.3 Outcome 1c: Prevalence of viral load suppression (VL<1000 copies/mL) among individuals on NNRTI-based first-line ART	8
4.4 Outcome 2a: Nationally representative measure of retention at 12 months	9
4.5 Outcome 2b: Prevalence of viral load suppression (VL<1000 copies/mL) among individuals receiving ART for 12 (\pm 3) months, adjusted for retention (or worst-case estimate of VL suppression)	9
4.6 Outcome 3a: Prevalence of HIVDR among individuals on ART with VL \geq 1000 copies/mL	10
4.7 Outcome 3b: Prevalence of HIVDR among individuals receiving first-line ART with VL \geq 1000 copies/mL	10
4.8 Outcome 3c: Prevalence of HIVDR among individuals receiving NNRTI-based first-line ART with VL \geq 1000 copies/mL	10
4.9 Outcome 4: Prevalence of HIVDR among individuals on ART	11
5. How to select clinics	12
5.1 Sampling very small or difficult-to-access clinics	12
5.2 Regional representation	13
5.3 Countries with many ART clinics	13
6. Survey among adults receiving ART for 12 (\pm 3) months	14
6.1 Patient eligibility criteria	14
6.1.1 Inclusion criteria	14
6.1.2 Exclusion criterion	14
6.2 Defining the survey sample size	14
6.2.1 Assumptions	14
6.2.2 Sample size calculations	14
6.2.3 Countries with few ART clinics	15

7. Survey among adults receiving ART for at least 48 months	16
7.1 Patient eligibility criteria	16
7.1.1 Inclusion criteria	16
7.1.2 Exclusion criterion	16
7.2 Defining the survey sample size	16
7.2.1 Assumptions	16
7.2.2 Sample size calculations	16
7.2.3 Countries with few ART clinics	17
8. Laboratory methods	18
8.1 Specimen collection, handling, processing and tracking	18
8.2 HIVDR genotyping and quality assurance of sequences	18
9. Implementation considerations	19
9.1 Duration of the survey, patient screening and sampling	19
9.2 List of variables to be collected	19
9.2.1 Patient-level information	19
9.2.1.1 Patient-level epidemiological and laboratory variables to be captured for all patients who will have blood drawn for VL assessment and genotyping	19
9.2.1.2 Minimum information to be captured for all eligible patients for at least the first three months from survey initiation	19
9.2.2 Clinic-level information	20
9.2.3 Survey-level information	21
9.3 Patient under-enrolment	21
9.4 Repeating the survey	21
9.5 Tools for country adaptation	21
9.6 Combining acquired HIVDR surveys with surveys of pre-treatment HIVDR	21
10. Data analysis	23
ANNEXES	24
Annex 1.1: Selecting the clinics to survey	24
Annex 1.2: Guaranteeing representation from all regions	26
Annex 1.3: Stratification	26
Annex 1.4: Data analysis plan	27
Annex 1.5: Reporting of HIVDR data	35
Annex 1.6: Calculating a nationally representative estimate of retention	35
Statistical Appendix	38
1. Sample size calculations: Prevalence of viral load suppression	38
2. Calculating the contribution to the design effect due to clustering of the outcome by clinic	39
3. Calculating the contribution to the design effect due to imperfect weighting information	40
4. Other sources of design effect	40
5. Calculating the sample size	40
6. Incorporating the finite population correction	41
7. Sample size calculations when all clinics are sampled	42
8. Sample size calculations for nationally representative estimate of retention	42
9. Estimated confidence interval width for Outcome 2b	43
10. Data analysis	43

ACKNOWLEDGMENTS

The work was led by Silvia Bertagnolio (World Health Organization), Jhoney Barcarolo (consultant) and Michael Jordan (Tufts University School of Medicine, USA). Statistical methods were developed by Natalie Exner Dean and Marcello Pagano (Harvard University, USA). Natalie Exner Dean wrote the statistical annexes and analysis plan. The concept note received substantial technical inputs and revisions by the HIVResNet Core Group (Emiliano Bissio, Argentina; Avelin Aghokeng, Cameroun; Elliot Raizes, USA; and Andrea De Luca, Italy).

Jos Perriens, coordinator of the Technologies and Commodities Team at the HIV Department, World Health Organization, provided overall supervision. We thank the United States Centers for Disease Control and Prevention, Atlanta, USA and the President's Emergency Plan for AIDS Relief (PEPFAR) HIV Drug Resistance working group for their critical inputs to the document.

We are most grateful to the HIVResNet Steering Group (Chunfu Yang, USA; Chris Archibald, Canada; Achara Teeraratkul, Thailand; Avelin Aghokeng, Cameroun; AM.J. Wensing, the Netherlands; Christopher Duncombe, USA; Kerry Dierberg, USA; Do Thi Nhan, Vietnam; Emiliano Bissio, Argentina;

Elliot Raizes, USA; Jonathan Shapiro, Israel; Natalia Nizova, Ukraine; Robert W. Shafer, USA; Wilford Kirungi, Uganda; Zhang Fujie, China; Tobias Rinke de Wit, the Netherlands; and Sergio Carmona, South Africa) for their strategic advice. We are also grateful to the contributions provided by WHO staff from regional and country offices.

Additionally, development of this guidance document benefitted greatly from inputs received from country ART programme managers and country representatives attending WHO regional workshops conducted in 2013 in Beijing, China; Brasilia, Brazil; Montpellier, France; Addis Ababa, Ethiopia; and Cape Town, South Africa. WHO is grateful to Amandine Cournil, Montpellier, France, for her review of the statistical annexes. Development and publication of this guidance was supported by the Bill and Melinda Gates Foundation (#38180); we are sincerely grateful for their support.

ACRONYMS

ADR	acquired HIV drug resistance
AIDS	acquired immunodeficiency syndrome
ART	antiretroviral therapy
ARV	antiretroviral drug
ATV/r	atazanavir/ritonavir
AZT	zidovudine (also ZDV)
DEFF	design effect
DBS	dried blood spot
DRV/r	darunavir/ritonavir
EFV	efavirenz
HIV	human immunodeficiency virus
ICC	intracluster correlation coefficient
HIVDR	HIV drug resistance
INI	integrase inhibitor
LPV/r	lopinavir/ritonavir
mL	milliliter
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
N(t)RTI	nucleotide reverse transcriptase inhibitor
NVP	nevirapine
PDR	pretreatment HIV drug resistance
PEPFAR	President's Emergency Plan for AIDS Relief
PI	protease inhibitor
PPS	probability proportional to size
PPPS	probability proportional to proxy size
PR	protease region
RT	reverse transcriptase region
SI	sampling interval
SID	survey identification number
VL	viral load
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNGASS	United Nations General Assembly Special Session
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27912

